WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, announced today that its 2018 Annual Meeting of Stockholders has been scheduled for April 25, 2018.
Additional information concerning the 2018 Annual Meeting will be included in Bioverativ’s 2018 Annual Meeting proxy statement, which will be filed with the SEC and mailed to Bioverativ’s stockholders at a later date. Stockholders intending to present a proposal or nomination for director at the 2018 Annual Meeting, whether or not for inclusion in the Bioverativ’s proxy materials, must follow the procedures and timelines set forth in the company's bylaws and applicable SEC rules.
Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in approximately two decades. For more information, visit bioverativ.com or follow @bioverativ on Twitter.